The 18-kDa mitochondrial translocator protein in human gliomas: An11C-(R)PK11195 PET imaging and neuropathology study

Journal of Nuclear Medicine

Volumn 56, Issue 4, 2015, Pages 512-517

  Su, Zhangjie ^a   Roncaroli, Federico ^b   Durrenberger, Pascal F ^b   Coope, David J ^a,c   Karabatsou, Konstantina ^c   Hinz, Rainer ^a   Thompson, Gerard ^a   Turkheimer, Federico E ^d   Janczar, Karolina ^b   Plessis, Daniel Du ^c   Brodbelt, Andrew ^e   Jackson, Alan ^a   Gerhard, Alexander ^a   Herholz, Karl ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

11c (r)pk11195; Glioma; Microglia; PET; Translocator protein

Indexed keywords

MITOCHONDRIAL PROTEIN; MITOCHONDRIAL TRANSLOCATOR PROTEIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBON; ISOQUINOLINE DERIVATIVE; LIGAND; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; TUMOR MARKER;

ADULT; ARTICLE; ASTROCYTOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MICROGLIA; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR CELL; BLOOD BRAIN BARRIER; BRAIN; BRAIN TUMOR; CELL TRANSFORMATION; DIAGNOSTIC USE; IMAGE GUIDED BIOPSY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; SCINTISCANNING; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CARBON RADIOISOTOPES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GLIOMA; HUMANS; IMAGE-GUIDED BIOPSY; ISOQUINOLINES; LIGANDS; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MALE; MICROGLIA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84928256223     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.151621     Document Type: Article

References (37)

1. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 2013;14:e370-e379.
2. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2014;232:165-177.
3. Terreno E, Uggeri F, Aime S. Image guided therapy: the advent of theranostic agents. J Control Release. 2012;161:328-337.
4. Ding H, Wu F. Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics. 2012;2:1040-1053.
5. Scarf AM, Kassiou M. The translocator protein. J Nucl Med. 2011;52:677-680.
6. Han Z, Slack RS, Li W, Papadopoulos V. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J Recept Signal Transduct Res. 2003;23:225-238.
7. Austin CJ, Kahlert J, Kassiou M, Rendina LM. The translocator protein (TSPO): a novel target for cancer chemotherapy. Int J BiochemCell Biol. 2013;45:1212-1216.
8. Denora N, Laquintana V, Trapani A, et al. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol Pharm. 2010;7:2255-2269.
9. Musacchio T, Laquintana V, Latrofa A, Trapani G, Torchilin VP. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm. 2009;6:468-479.
10. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa Translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1-5.
11. 18F-N-fluoroacetyl-N-(2,5-dimethox-ybenzyl)-2-phenoxyaniline. J Nucl Med. 2011;52:107-114.
12. 18F-fluoroethoxy)phenyl)-5,7-fimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med. 2012;53:287-294.
13. 18F] DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging. 2012;39:811-823.
14. 11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur J Nucl Med Mol Imaging. 2013;40:1406-1419.
15. 11C]PK 11195 in vivo after induction of a cortical ischaemic lesion. Int J Rad Appl Instrum B. 1992;19:159-166.
16. 11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol. 1994;21:573-581.
17. Cízek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD. Fast and robust registration of PET and MR images of human brain. Neuroimage. 2004;22:434-442.
18. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
19. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
20. Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR. 2005;26:266-273.
21. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology. 2002;224:797-803.
22. Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR. 2007;188:204-212.
23. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
24. Cornu P, Benavides J, Scatton B, Hauw JJ, Philippon J. Increase in omega 3 (peripheral-type benzodiazepine) binding site densities in different types of human brain tumours: a quantitative autoradiography study. Acta Neurochir (Wien). 1992;119:146-152.
25. Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neurooncology. Lancet Neurol. 2007;6:711-724.
26. Herholz K, Langen KJ, Schiepers C, Mountz JM. Brain tumors. Semin Nucl Med. 2012;42:356-370.
27. 11C-(R)-PK11195 in patients with Alzheimer's disease. J Nucl Med. 2008;49:1249-1256.
28. 11C-methionine positron emission tomography. J Neurosurg. 2011;114:1640-1647.
29. 11C-methionine: report of two cases. J Neurooncol. 2011;101:335-341.
30. Vlodavsky E, Soustiel JF. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neurooncol. 2007;81:1-7.
31. Miettinen H, Kononen J, Haapasalo H, et al. Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res. 1995;55:2691-2695.
32. Takaya S, Hashikawa K, Turkheimer FE, et al. The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. J Neurooncol. 2007;85:95-103.
33. Venneti S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/macrophages in the brain. Glia. 2013;61:10-23.
34. Wei J, Gabrusiewicz K, Heimberger A. The controversial role of microglia in malignant gliomas. Clin Dev Immunol. 2013;2013.
35. Kaur C, Dheen ST, Ling EA. From blood to brain: amoeboid microglial cell, a nascent macrophage and its functions in developing brain. Acta Pharmacol Sin. 2007;28:1087-1096.
36. Agnello D, Carvelli L, Muzio V, et al. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J Neuroimmunol. 2000;109:105-111.
37. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971-988.